As healthcare systems around the world face unprecedented challenges, the fight against infectious diseases is more important than ever. Vaccines remain the most important tool available to us for protecting against epidemics and outbreaks, and Pfizer is proud to partner with Gavi, the Vaccine Alliance to ensure millions of children are protected against pneumococcal disease.
At the Global Vaccine Summit, held virtually on 4th June, Pfizer was proud to renew its commitment to Gavi for its next replenishment period. This builds on a more than decade-long partnership in which we supplied more than 500 million doses of our pneumococcal vaccine to reach more than 20 million children each year in some of the world’s most vulnerable communities.
We are committed to partnering with Gavi for the future to safeguard and extend the gains from immunization services and protect even more children from pneumococcal disease through both our current and next generation vaccines. These vaccines will help to save lives, reduce the burden of disease on communities, help families and communities to live fuller lives and help to drive economic growth.